Please assess the completion status of the following clinical trial:

Trial Title: Novel Induction to Buprenorphine/Naloxone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment with Bicycle Health services~* Aged 18 years old or older~* Diagnosis of opioid use disorder confirmed by DSM-5 criteria~* In no/mild withdrawal at the time of intake~* Need to undergo induction to buprenorphine from a full opioid agonist~* Use of full opioid agonists not directly from a pharmacy within the last 24 hours~* Pharmacy stock check of 2 mg film/tablet done before visit~* Willingness and ability to follow study protocols, and the ability to provide informed consent~Exclusion Criteria:~* Known allergy or sensitivity to buprenorphine/naloxone~* Any circumstance that precludes the need for induction~* In moderate to severe withdrawal at the time of intake~* Severe or complex medical/psychiatric comorbidity that requires a customized induction schedule or surveillance~* Any element that would exclude an individual from Bicycle Health services in general (e.g., homelessness, severe untreated mental illness)~* Patients requesting specific induction technique~* Patients who are pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Traditional Induction Arm (Type: ACTIVE_COMPARATOR): In this arm, study participants will wait until they have significant opioid withdrawal (SOWS score \>=17) prior to starting buprenorphine. Participants will then started with 2 mg sublingual and escalate to a maximum of 12 mg on the first day depending on withdrawal symptoms. On day 2, the participant will take same dose as the total dose taken on day 1, and continue that dose daily until reevaluation.
- Microdosing Induction Arm (Type: ACTIVE_COMPARATOR): In this arm, study participants will not wait until they have significant opioid withdrawal. They will take 0.5 mg buprenorphine on day 1, 2 mg on day 2, 4 mg on day 3, 6 mg on day 4, 8 mg on day 5 and 12 mg starting on day 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).